Studies show that Avastin can prolong the lives of patients with late-stage breast and lung cancer by several months when the drug is combined with existing therapies. Genentech expects to seek federal approval later this year to sell it specifically for those diseases. But even now, doctors, who are free to prescribe the drug as they see fit, are using Avastin for some breast and lung cancer cases — and finding its cost beyond the means of some patients.
~
With colon cancer, a year of Avastin treatment costs about $50,000. But the drug will be used at higher doses for lung and breast cancer, and Genentech does not plan to reduce the unit price, even though the additional cost of producing a higher dose is minimal. Roche executives described the pricing plans were described in a recent interview.
~
Avastin is currently used mainly in cases of late-stage colon cancer, a disease that affects about 50,000 Americans annually. On average, those patients take the drug for 11 months and it extends their lives an average of 5 months, compared with other treatments.
http://www.nytimes.com/2006/02/15/business/15drug.html?_r=1&pagewanted=all
Sounds like Genetech plans to rip off people dying from breast cancer to me